In their recent article, Kovach et al1 reported successful treatment of multicentric reticulohistiocytosis (MR) with etanercept. Their patient was treated with a 25-mg subcutaneous injection of etanercept biweekly, 20 mg of prednisone daily, and 15 mg of methotrexate by mouth weekly and showed improvement in skin and joint symptoms within 1 month. We report a less successful application of etanercept in the treatment of MR.